Gilead Sciences stock
Price history
+34.25% over the period1 year: from $125.20 (November 13, 2025) to $168.08 (November 13, 2026), +34.25%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $168.08 |
| October 30, 2026 | $170.68 |
| September 30, 2026 | $149.05 |
| August 31, 2026 | $146.34 |
| July 31, 2026 | $130.21 |
| June 30, 2026 | $126.34 |
| May 29, 2026 | $134.43 |
| April 30, 2026 | $130.84 |
| March 31, 2026 | $139.37 |
| February 27, 2026 | $148.95 |
| January 30, 2026 | $141.95 |
| December 31, 2025 | $122.74 |
| November 28, 2025 | $125.84 |
| November 13, 2025 | $125.20 |
At a glance
The company
Biopharmaceutical company discovering and commercializing medicines for HIV, hepatitis B and C, cancer immunotherapies, fungal infections and COVID-19
Latest results
Quarter to September 30, 2026 · EPS $2.55 (estimate $2.12)
Dividend
TickerLandia's take on Gilead Sciences
- Pricier than usual relative to earnings: P/E on the latest fiscal year 25 vs a median of 18 over its last 9 fiscal years.
- Strong point: Market momentum (85/100 in its group). Weak point: Dividend (27/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.81% from the 52-week high
Analysts · 28 analysts
Average target$174.77+3.98% vs. price
Buy 22 · Hold 5 · Sell 1 · Buy
TickerLandia Fingerprint: Gilead Sciences
Compared with similar companies: very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh78
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 16.6 60 EV/EBITDA 15.5 78 Price/book 16.0 90 Price/sales 6.73 82 Profitabilityaverage50
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 38.2% 86 Gross margin 79.9% 82 ROA 13.5% 78 Net margin −12.5% 2 ROE −22.4% 2 Earnings stabilitylow28
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 12.1% 2 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthlow32
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +2.57% 34 Revenue growth (year over year) +6.80% 42 Earnings growth (year over year) −20.20% 19 Financial strengthlow31
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.23 30 Interest coverage 11.5 38 Current ratio 1.38 50 Debt/equitycounts in reverse: lower means more financial strength 2.02 6 Dividendlow27
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 12 years 14 Dividend yield 2.0% 40 Payout ratio 43.5% 27 Market momentumvery strong85
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +25.49% 96 1-year return +34.25% 76 Distance from 200-day average +18.60% 87 Relative strength (6 months) +24.37% 82 Risklow33
How much the price swings.
Metric Value Position in group Volatility (60 days) 26.7% 29 Beta (1 year) 0.41 36 Maximum drawdown (12 months) 22.0% 32
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Gilead Sciences is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Gilead Sciences's P/E today is 24.8, above the median of its last 9 fiscal years (18.0; between 7.20 and 243.1 from 2016 to 2025). Gilead Sciences's Forward P/E: 16.6, in line with the median of a group of 11 similar companies (16.5).
Compared with 11 similar companies
| Metric | Gilead Sciences | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 16.6 | Middle | |
| Operating margin | 38.2% | High | |
| ROE | -22.4% | Low | |
| Debt/equity | 2.02 | High | |
| Price/book | 16.0 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Gilead Sciences. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$8.3B
Latest quarter · Q3 2026
Net income
$2.43B
Latest quarter · Q3 2026
Quarterly net margin
29.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $208.48B
- EPS
- -$3.13
- Volume
- 3.64M
- Daily trading
- €978.33M
- Dividend yield
- 1.93%
How Gilead Sciences is changing
All resultsRevenue grew 3.6% a year on average over the last 5 years
Operating margin rose from 26.9% to 34.0%
Profits turn into cash: free cash flow equal to 185% of net income
Returns
Gilead Sciences returns with dividends
$1,000 invested in Gilead Sciences 5 years ago, on November 15, 2021, would be worth $2,987 today with dividends reinvested: +198.67% in total, +24.50% per year. On price alone it would be $2,501 (+150.12%).
| Period | Gilead Sciences | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +13.63% | −3.12% | $1,136 |
| 6 months | +26.33% | +1.58% | $1,263 |
| Year to date | +36.94% | +10.46% | $1,369 |
| 1 year | +37.56% | +12.23% | $1,376 |
| 3 years | +146.53% | +71.41% | $2,465 |
| 5 years | +198.67% | +61.48% | $2,987 |
| 10 years | +212.03% | +249.40% | $3,120 |
Over the last 6 months it has done better than 64% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Gilead Sciences: technical analysis
Gilead Sciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.7% below its all-time closing high ($174.48, November 4, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 59
- Between 30 and 70
- vs 200-session average
- +18.60%
Support and resistance
Price areas where Gilead Sciences has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$168.08
- Support$153.38−8.75%2 touches, last on September 23, 2026
- Support$142.59−15.16%7 touches, last on October 6, 2026
- Support$137.29−18.32%5 touches, last on August 5, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.41
- Volatility (60 sessions, annualised)
- 26.7%
- Largest fall in the last year
- −22.03%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Gilead Sciences: seasonality
Average monthly price change over 35 years
Over the last 35 years, the strongest month for Gilead Sciences has been January: +4.49% on average, positive in 20 years out of 34. The weakest has been March: −1.14% on average, positive in 17 years out of 35. November, the current month, has been positive in 22 years out of 34 (+3.97% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.49% | +4.97% | 20 of 34 |
| February | +0.84% | −1.24% | 15 of 35 |
| March | −1.14% | −0.02% | 17 of 35 |
| April | +0.99% | +0.05% | 18 of 35 |
| May | +2.06% | +2.74% | 20 of 35 |
| June | +2.32% | +2.09% | 22 of 35 |
| July | +1.65% | +1.86% | 20 of 35 |
| August | +3.57% | +0.61% | 20 of 35 |
| September | +3.09% | +1.56% | 20 of 35 |
| October | +0.72% | +0.48% | 19 of 35 |
| November | +3.97% | +4.69% | 22 of 34 |
| December | +1.01% | −1.35% | 13 of 34 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Gilead Sciences and its competitors
Based in Foster City, California, Gilead Sciences was incorporated in 1987 and works as a biopharmaceutical company that discovers, develops and commercializes medicines for areas of unmet medical need. Its HIV portfolio includes Biktarvy, Descovy and Genvoya, and it also offers the hepatitis treatments Epclusa and Vemlidy, the antifungal AmBisome and the COVID-19 treatment Veklury. In cancer and cell therapy it markets Yescarta, Tecartus and Trodelvy, and it develops immunotherapies for cancer and other serious diseases.
- Headquarters
- Foster City, United States
- Employees
- 17,000
- Founded
- 1987
- Chief executive
- Daniel Patrick O'Day
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| PfizerPFE | $164.67B | 29.1% | 41.3 | +11.29% |
| Bristol-Myers SquibbBMY | $129.66B | 32.4% | 14.1 | +12.48% |
| MerckMRK | $364.26B | 35.2% | 147.8 | +30.24% |
| AbbVieABBV | $521.5B | 36.6% | 50.6 | +41.50% |
Same industry or related industries, similar size. Compare Gilead Sciences with its competitors · Full profile
